Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2020
Price :
$35
*
At a glance
- Drugs Rapastinel (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Allergan
- 22 Apr 2019 Status changed from active, no longer recruiting to completed.
- 06 Mar 2019 According to an Allergan media release, an interim analysis of this study suggests the primary and key secondary endpoints will not be met. Interim analysis was conducted of the primary and secondary efficacy endpoints of all randomized patients in the double-blind treatment period. At the time of the analysis, all patients had completed all visits relevant for determining a relapse.
- 05 Sep 2018 Status changed from recruiting to active, no longer recruiting.